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Wiisanen et al. (1) performed a meta-analysis of 23 studies
comparing drug-eluting stents (DES) with bare-metal stents for
saphenous vein graft lesions, and they demonstrated the supe-
riority of DES in reducing death, myocardial infarction, and
target vessel revascularization. Eleven meta-analyses have been
published thus far on the same subject in a little over 1 year,
whereas the number of primary studies has remained more or
less the same (29 studies involving 7,994 patients) (2). All these
meta-analyses have yielded similar results showing that DES
reduced the risk of major adverse cardiac events predominantly
driven by a lower target lesion revascularization. So how does the
meta-analysis by Wiisanen et al. (1) add new information? Specifi-
cally, the investigators have included “duplicate” data. They have
included 4 randomized controlled trials. In reality, there are only 2
randomized comparisons of DES with bare-metal stents for saphe-
nous vein graft lesions—the SOS (Stenting of Saphenous VeinGrafts)
and RRISC (Reduction of Restenosis In Saphenous Vein Grafts With
Cypher Sirolimus-Eluting Stent) trials. Wiisanen et al. (1) have included
both short- and long-term outcome studies for the RRISC trial (same
patient population counted twice). The third included randomized
controlled trial is a subgroup analysis from the BASKET (Basal Stent
Cost-Effectiveness Trial) and not a randomized comparison. Analyzing
the data on the same patients more than once may lead to significantly
biased estimates of efficacy and safety (3).
We identified 11 meta-analyses (and perhaps a few more in
the pipeline) with more than 8 published in 6 months by
different investigators (Online Table 1). Is there any “novelty”
in terms of incremental scientific value of these publications or
are they just redundant. Which of these 11 papers should be
cited and what would be the criteria? Is the criterion the number
of studies and included patients? Publication date? Quality of
the meta-analysis? Or the reputation of the journal? These
issues and their potential negative impact have been raised by a few
reports (3–5). It might be a consequence of multiple cardiology
journals with rapid review turnaround times, online publication ahead
of print, and so forth, so we believe reorganizing the process in which
meta-analyses are conceived, designed, executed, and reviewed could
help address some of these issues (4,5). Authors should be required to
submit their proposals in a central registry like clinicaltrials.gov or
others recently proposed (5). Submitted meta-analysis should be
rigorously evaluated for accuracy of data and careful scrutiny to avoid
issues such as overlapping/redundant data. Further evaluation of
statistical methods by a dedicated statistician (as mandated by a few
journals) would also be helpful. Journals should lay out comprehensive
guidelines for meta-analysis in their “Instructions for Authors” sec-
tion.
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APPENDIX
To see a table with the details of the 11 meta-analyses referred to in the text,
please see the online version of this paper.
Drug-Eluting Stents for
Saphenous Vein Graft Interventions
I read with interest the meta-analysis by Wiisanen et al. (1)
regarding stents in saphenous vein graft interventions. I was
surprised to see that the RRISC (Reduction of Restenosis In
Saphenous vein grafts with Cypher sirolimus-eluting stent) trial
is counted twice in the analysis of the randomized controlled
trials. This study included 38 patients in the drug eluting stents
(DES) and 37 in the bare-metal stents categories. The initial
publication reports the 6-month outcome (2), whereas the
second publication reports long-term outcome of the same
patients (3). Counting these patients twice is obviously wrong.
Unfortunately, this error leads to wrong conclusions such as, for
example, the conclusion from the correct analysis of mortality in
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591randomized controlled trials should be that DES are associated
with increased mortality (17 deaths of 113 DES and 4 deaths of
89 bare-metal stents; p 0.027). This is in contradiction to the main
conclusion of this manuscript that “DES use was associated with
improved mortality.” It is hard, if not impossible, to justify such a
conclusion even if it is supported by nonrandomized cohort trials data
when the randomized controlled trials data are contradictory. I believe
the message to the readers from this manuscript is misleading,
therefore, I believe the entire manuscript should be rewritten with the
correct analysis and conclusions.
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Reply
We would like to thank the authors of the letters for their
interest in our paper (1). We agree that the RRISC (Reduction
f Restenosis In Saphenous vein grafts with Cypher sirolimus-
luting stent) and DELAYED RRISC (Death and Events at
ong-term follow-up AnalYsis: Extended Duration of the
eduction of Restenosis In Saphenous vein grafts with Cypher
tent) trials included the same patients (2,3). On the basis of the
re-specified criteria for the meta-analysis, we included all
ublished trials on the use of drug-eluting stents (DES) versus
are-metal stents (BMS) in vein graft percutaneous coronary
ntervention (PCI). Because the included studies were weighted
n the basis of study size, and because this particular study was
mall in size (only 75 patients), we did not anticipate any
ignificant impact of this strategy on the overall conclusions.
e analyzed the data with and without inclusion of thehort-term RRISC data and found no significant differences inthe conclusions. Drug-eluting stent use was associated with
reduced mortality when early and delayed RRISC data were
included (odds ratio [OR]: 0.72; 95% confidence interval [CI]: 0.58
to 0.89), and there was no significant difference when the early
RRISC data were excluded (OR: 0.72; 95% CI: 0.58 to 0.89) (Fig.
1A). Similarly, DES use—including early RRISC data—led to
reduced target vessel revascularization (OR: 0.56; 95% CI: 0.40 to
0.77). Excluding these data, there was no significant change in the
estimated benefit of DES on target vessel revascularization (OR:
0.58; 95% CI: 0.42 to 0.77) (Fig. 1B). Identical conclusions were
made when other adverse outcomes were analyzed with and
without inclusion of early RRISC events.
Despite the statistically significant reduction in mortality
associated with DES in our overall analysis, we clearly stated in
the discussion that this is possibly caused by selection bias. We
emphasized that this finding was primarily noted in the cohort
trials and not in randomized trials, hence reinforcing the notion
that it might have been driven by interventional operators
selecting healthier patients to implant DES. We referenced the
work by Shishehbor et al. (4), who made similar observations.
Because of that concern, we opted not to state that mortality
benefit in our final conclusions paragraph in the published paper
(1). The meta-analysis of the body of literature supports the fact
that DES use in vein graft PCI is safe and not associated with
increased risk of adverse events or mortality, despite the
limitations and as noted in the conclusions paragraph. This
remains our conclusion and that of others who performed
similar meta-analyses (5–9).
We agree with the criticism of the multiplicity of meta-
analyses performed on the same subject. We believe this is the
effect of the publication and peer-review process as it works
today. It is likely that—given the time it takes from writing the
manuscript to submission, review, and response to editorial
revisions—most of these manuscripts were making their way
through the process at different journals at the same time, thus
making it difficult to know that each of these papers was in press. As
stated, this can be avoided with the creation of a central repository of
systematic reviews and meta-analyses for authors to submit to as well as
be aware of similar projects in development. Given the number of
independent journals dedicated to cardiology and its subspecialties, this
might not be an easy task.
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